Non-Hodgkin Lymphoma Perspective

 
 
  • Is Cell-Based Immunotherapy Entering the Mainstream?   Experts in cell-based therapies for cancer discuss opportunities and obstacles in their wider use beyond academic centers.
  • CAR T Cell Therapy: 'It's the Real World Now'   Drs Jacobson, Miklos, and Maus unveil 'provocative and exciting' research at ASH 2018 in CAR T cell therapy.
  • Venetoclax Shows Benefits Across a Range of Hematologic Cancers   From ASH 2018, Ann LaCasce and Jennifer Crombie from Dana-Farber discuss new trial data on venetoclax, a potent, selective inhibitor of BCL2.
  • Oncologists' Off-Label Prescribing Pits Access Against Reimbursement Off-label prescribing in oncology is undergoing a change: Payers are more restrictive in their reimbursement for off-label uses, while oncologists are keen to provide access to new immunotherapies.
  • Non-Hodgkin Lymphoma: Victory Lap   The team discusses the postinfusion period, when adverse effects are most common, and addresses remaining questions for the future of this innovative therapy.
  • 5 Things to Know About Chronotherapy With the 2017 Nobel Prize in Medicine being awarded to research on circadian rhythms, the time has come to take a look at synchronizing chemotherapy with the body's natural clock. Here are five things you should know about chronotherapy.
  • Non-Hodgkin Lymphoma: All Systems Go   The Moffitt team discusses patient referral and selection, as well as the extensive preparation candidates undergo before receiving CAR T-cell infusion.
  • Cost Problem Only Getting Worse With IO Combos, Adjuvant Use   Drs Weber and Hamid discuss the increasing cost of immune-oncology therapy, particularly concerning as the number of patients using these agents in the adjuvant setting is likely to rise greatly.
  • EHA 2018 Read clinically focused news coverage of key developments from EHA 2018
  • IWMF 2018 Read clinically focused news coverage of key developments from IWMF 2018
  • Non-Hodgkin Lymphoma: Test-Driving CAR T-Cell Therapy   CAR T-cell therapy is redirecting treatment and redefining the model of care for patients with relapsing lymphoma. The vanguard Moffitt team discusses the issues involved in this breakthrough therapy.
  • 'Real World' CAR T Cells: Comparing and Using Approved Products   Drs Perales and Pasquini discuss the rapidly advancing field of CAR T and how patient safety and choice can be managed during these unprecedented times.
  • Comparing CAR T-Cell Therapies in Lymphoma   Drs Ann LaCasce and Caron Jacobson on how these and other treatments may change your practice in the new year.
  • Top News From ASH 2017: Slideshow Hot topics include moving to newer oral anticoagulants for cancer patients with VTE, plus practice-changing results in chronic lymphocytic leukemia, multiple myeloma, and Hodgkin's lymphoma.
  • Safety With CAR T-Cell Therapy   Dr Stephan Grupp tells the 'inside story' of issues raised at the recent FDA Oncology Drug Advisory Committee meeting on CAR T-cell therapy.
  • Readers' Picks: Rising Stars of Healthcare Research Medscape readers nominate colleagues who represent America's pool of inspiring and pioneering researchers in medicine and healthcare.
  • European Hematology Association (EHA) 2017 Congress Read clinically focused news coverage of key developments from EHA 2017.
  • Biomarkers to Determine Who Gets Checkpoint Inhibitors   Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.
  • Top News From ASH 2016: Slideshow Practice-changing research in lymphoma and leukemia, plus growing excitement over two chimeric antigen receptor (CAR) T cell products, featured prominently at this year's meeting.
  • Negative Trials, CAR T Studies Lead ASH Lymphoma Highlights   Drs Ann LaCasce and Kerry Savage discuss the most interesting lymphoma studies presented at ASH 2016, including the CALGB/Alliance 50303, GOYA, and GALLIUM trials.